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IS AVAILABILITY OF ARTESUNATE ASSOCIATED WITH THE PROGNOSIS OF IMPORTED 
MALARIA IN SPAIN? 
 
Dear Editor, 
Although there is a lot of aspects we stil need to understand about treatment with 
artemisinins[1], there is no doubt about their efficacy in treating malaria. Artesunate 
(AS) has demonstrated its superiority against quinine for treatment of severe malaria 
in terms of reduction of mortality in different randomized clinical trials performed in 
endemic countries and subsequent meta-analysis[2-4]. Despite having been 
established as the first line treatment by WHO and several national guidelines[5,6], its 
full implementation in non-endemic countries has not been completed. 
We performed a cross-sectional study to assess the impact of accessibility of AS for 
treating imported malaria in Spain. Data about malaria cases admitted in different 
hospitals of Spain was obtained from the public National Health System database 
(CMBD) from 2007 to 2017, aggregated by different autonomous communities (a first-
level political and administrative division). Information about availability of AS was 
obtained through two rounds of calls to pharmacies of the non-monographic public 
hospitals in Spain. The primary outcome for the analysis was defined using aggregated 
mortality rates and a secondary outcome was defined using a composite outcome 
defined as death during admission or prolonged hospitalization (> 7 days)).  
Data about availability of AS was obtained from 183 (55.1%) of the 332 public hospitals 
inquired. The answer was similar regardless the hospitals size: 59.2% (74/125) of 
hospitals with ≥500 beds, 55.6% (55/99) of hospitals with 200-499 beds and 50.0% 
(54/108) of hospitals with <200 beds (p=0.369). AS was available in 45.9% (84/183) 
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hospitals, being the first treatment option for severe malaria in 84.0% (68/81) of them 
(3 hospitals missing data). A decreasing trend in availability of AS was observed 
depending on the hospital size (73.0% for ≥500 beds hospitals vs 47.3% for 200-500 
beds hospitals vs 7.4% for <200 beds hospitals, p-for-trends < 0.001).   
Between 2007 and 2017, 7731 malaria cases were reported, with an overall mortality 
of 1%. A significant reduction in mortality was found when the first and the second 
study period were compared (1.3% in 2007-2011 vs 0.8% in 2012-2017, p=0.027). 
Median length of hospitalization did not differ between death and survival cases (5 
days (IQR 2-14); 4 days (IQR 3-6), p=0.105). Age > 65 years (OR 6.8, 95%CI 3.6-12.6) 
and foreign origin (OR 4.3, 95%CI 1.5-12.1) were found to be associated with higher 
mortality in an adjusted regression model (Table). A decrease in the incidence of the 
secondary outcome was observed in those autonomous communities in which AS was 
introduced in at least 25% of hospitals before 2015 (Median 30.8% [IQR: 24.0-33.9%] 
vs 20.7% [IQR: 18.7-24.8%], p=0.049).  
In conclusion, availability of AS seems to be associated with a better outcome in 
patients with imported malaria attending Spanish hospitals. The lack of AS is especially 
worrying in smaller hospitals. Although these hospitals are less likely to admit severe 
malaria cases, usually transferred to tertiary specialized units, availability of AS in any 
health-care facility regardless its size is essential to ensure patients to receive an 
adequate treatment as soon as possible. Accessibility to health-care facilities may have 
an impact on mortality and prolonged hospitalization, as it could be the case of 
vulnearable populations such as patients of foreign origin. Our results reinforce the 
importance of ensuring a proper distribution and availability of AS in hospitals in non-
endemic countries, as well as the need of promoting policies to optimize the access to 
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health care systems for all citizens, in order to improve the outcome of imported 
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Table – Factors associated with mortality and long hospitalization in malaria patients admitted to hospital in 
Spain (2007-2017).   
 Descriptive analysis Bivariate analysis Adjusted analysis 













































4.30 (1.53 – 12.10) 
 
0.006* 
















































Table – Descriptive, bivariate and multivariate analysis of factors associated with mortality and long hospitalization 
in malaria patients admitted to Spanish hospitals between 2007 and 2017. Primary outcome defined as mortality 
during hospitalization. Secondary outcome defined as death during admission or prolonged hospitalization (> 7 
days).  
* Statistically significant p- values.  
 
